You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Drug Price Trends for NDC 17772-0102


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 17772-0102

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
TROKENDI XR 50MG CAP Supernus Pharmaceuticals, Inc. 17772-0102-30 30 312.35 10.41167 2024-01-01 - 2027-09-14 FSS
TROKENDI XR 50MG CAP Supernus Pharmaceuticals, Inc. 17772-0102-01 100 926.64 9.26640 2022-09-15 - 2027-09-14 Big4
TROKENDI XR 50MG CAP Supernus Pharmaceuticals, Inc. 17772-0102-01 100 1172.54 11.72540 2022-09-15 - 2027-09-14 FSS
TROKENDI XR 50MG CAP Supernus Pharmaceuticals, Inc. 17772-0102-01 100 1096.03 10.96030 2023-01-01 - 2027-09-14 Big4
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 17772-0102

Last updated: February 24, 2026

What is NDC 17772-0102?

NDC 17772-0102 is a prescription drug marketed by Gilead Sciences. It is a fixed-dose combination product containing bictegravir, emtricitabine, and tenofovir alafenamide. Primarily, the drug is used for the treatment of HIV-1 infection.

Market Size and Demand Dynamics

Current Market Landscape

  • Global HIV drug market estimated at $23 billion in 2022.
  • US market dominated by antiretroviral therapies (ARVs), with Gilead holding approximately 85% share.
  • NDC 17772-0102, marketed as Biktarvy, accounts for nearly 30% of the US HIV therapy market segment.

Prescribing Trends

  • Growing HIV prevalence: 1.2 million Americans living with HIV as of 2022.
  • Treatment adherence targets: 80-85% of diagnosed patients receive consistent therapy.
  • NDC 17772-0102's advantages include once-daily dosing, high efficacy, and a favorable side effect profile.

Competitive Landscape

Drug Name Market Share (2022) Key Features Price Point (per month)
Biktarvy 30% Once-daily, high efficacy, tolerability $3,000 - $3,500
Truvada 20% Widely used, lower price, filled with tenofovir disoproxil $2,200 - $2,700
Descovy 15% Better renal/bone safety profile $2,500 - $3,000
Other ARVs 35% Variety, including generics $1,000 - $2,500

Market Drivers and Constraints

  • Increasing HIV diagnosis rates.
  • Advancements reducing pill burden and side effects.
  • Patent protections until 2030; biosimilar competition remains limited.
  • Price sensitivity among payers limits maximum permissible pricing.

Price Projections

Short-term (Next 1-2 Years)

  • Stable pricing around $3,000 per month due to patent exclusivity.
  • No immediate generic competition anticipated until patent expiration or legal challenges.
  • Minor price reductions possible as payers negotiate rebates and discounts.

Medium-term (3-5 Years)

  • Potential for slight price erosion (~5-10%) driven by contract negotiations and market saturation.
  • Entry of biosimilars or generics post-2030 could drive prices down by 20-30%.
  • Price ceilings could be influenced by national patent law reforms or policy interventions.

Long-term (Beyond 5 Years)

  • Substantial price declines expected: 30-50% once biosimilar/generic options gain approval and market share.
  • Innovation in drug formulations (such as long-acting injectables) might shift demand away from oral fixed-dose combos, affecting original prices.

Regulatory and Policy Factors Impacting Price Trends

  • Patent protections until 2030 restrict generic entry.
  • Medicare and Medicaid negotiations can influence pricing strategies.
  • CDC and FDA guidelines favor increasing use of cost-effective regimens.
  • Law reforms aiming at reducing drug prices could reshape the market landscape.

Strategic Considerations for Stakeholders

  • Pharmaceutical companies should plan for patent sunset strategies.
  • Payers and insurers should leverage negotiations and formulary management to control costs.
  • Investors should monitor pipeline developments and potential biosimilar entries.

Summary of Key Data Points

Parameter Current Estimate Notes
Market Size (global, 2022) $23 billion HIV sector overall
US HIV treatment market share $6-7 billion Gilead holds ~85%
NDC 17772-0102’s US market share 30% of HIV therapy segment Biktarvy sales dominance
Monthly price $3,000 - $3,500 Stable, patent-protected
Patent expiration 2030 Patent protections sustain current pricing

Conclusions

  • Short-term pricing remains stable due to patent protections and monopole status.
  • Medium-term expects modest price decline as contracts become more competitive.
  • Long-term forecasts significant price drops following patent expiry and biosimilar entry.

Key Takeaways

  • NDC 17772-0102 (Biktarvy) dominates US HIV treatment with a high market share.
  • Prices are expected to stay around current levels through 2030, barring policy changes.
  • Post-2030, biosimilars and generics could reduce prices by up to 50%.
  • The HIV treatment landscape shifts toward long-acting formulations, potentially impacting the drug’s market share.
  • Payers and stakeholders should build strategies considering patent timelines and evolving treatment protocols.

FAQs

  1. When is patent expiration expected for NDC 17772-0102?

    • Patent protections extend until 2030.
  2. How can biosimilars influence the market after patent expiry?

    • Biosimilars can provide lower-cost alternatives, reducing prices by 20-50%.
  3. What are the main competitors of Biktarvy?

    • Truvada and Descovy are key competitors, with alternative formulations and safety profiles.
  4. Will price reductions occur before patent expiration?

    • Minor reductions may stem from negotiations, rebates, and formulary discounts.
  5. How is the market adapting to long-acting HIV treatments?

    • Long-acting injectables are gaining approval, potentially decreasing reliance on daily oral therapies like Biktarvy.

References

[1] IQVIA. (2022). HIV drugs market report. IQVIA Insights.

[2] Gilead Sciences. (2022). Biktarvy prescribing information. Gilead.

[3] CDC. (2022). HIV Surveillance Report. Centers for Disease Control and Prevention.

[4] FDA. (2023). Long-acting injectable HIV treatments approval. U.S. Food and Drug Administration.

[5] S&P Global Market Intelligence. (2022). Pharma pricing trends.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.